Opendata, web and dolomites

BIOCOPY SIGNED

BIOCOPY: the new biomolecule copying and screening solution for diagnostics and therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BIOCOPY project word cloud

Explore the words cloud of the BIOCOPY project. It provides you a very rough idea of what is the project "BIOCOPY" about.

rna    freiburg    assay    technique    diagnostics    team    upfront    cheaper    milestone    protein    expertise    60    covers    pharmaceuticals    2025    photocopier    100    antibodies    physics    dna    off    binding    analogous    opens    output    revenues    candidates    days    biotech    transfer    spin    copy    tailor    coatings    market    company    royalty    projected    template    completely    patented    discovery    manufacturing    vaccines    microsystems    label    coated    character    therapeutics    world    billion    11    drug    dimensions    services    university    surface    annum    biotechnology    technological    mixes    commercialization    responsible    disruptive    biocopy    biology    awarded    engineering    2019    borned    describing    first    academic    plan    companies    either    molecular    innovative    approval    molecules    enzymes    line    pharma    feasibility    dollar    generation    clinical    catalysts    free    5m    copied    business    biosensors    acute    biochemical    recovered    supplying    screenings    payments    obtaining    biomolecules    bioactive    made    vaccine   

Project "BIOCOPY" data sheet

The following table provides information about the project.

Coordinator
BIOCOPY GMBH 

Organization address
address: SPECHTWEG 25
city: FREIBURG IM BREISGAU
postcode: 79110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.biocopy.de/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOCOPY GMBH DE (FREIBURG IM BREISGAU) coordinator 50˙000.00

Map

 Project objective

'BioCopy is a spin-off company borned in the University of Freiburg. We have developed an innovative, patented technique to copy biomolecules analogous to a photocopier. A DNA-coated surface is used as copy template. By supplying different biochemical 'copy mixes', either a DNA, a RNA or a protein copy is generated. After the copy process, the copied biomolecules can be analyzed label-free for their specific binding to target molecules and recovered as potential candidates for a future use as therapeutics or diagnostics. The BioCopy technology completely opens up new dimensions for drug development, vaccines, antibodies, enzymes, catalysts, bioactive coatings, and biosensors and it has are more than 40 future applications. We plan to offer 3 products and services to pharma and biotech companies, related with high- output and cheaper molecular biology screenings. The most promising line is the tailor-made discovery of vaccine candidates within two days. This will have a disruptive character, because the first generation of a vaccine is a billion-dollar market, projected to rise $60 billion on 2019, with 11% growth per annum, and to $100 billion by 2025. BioCopy will provide vaccine candidates to pharmaceuticals, obtaining revenues through upfront, milestone and royalty payments, and they will be responsible for the vaccine´s clinical development, approval and distribution. The multi-awarded BioCopy team covers business know-how and expertise in biology, physics, manufacturing systems engineering, assay development and microsystems technology. BioCopy aims to contribute to the European challenges related with advanced biotechnology applications in pharma sector, and to increase the technological transfer from the academic world into the manufacturing sector. During phase 1 we will build up a detailed business plan and a feasibility study, describing all the needed activities in order to reach BioCopy commercialization. We will need about €2.5M in phase 2.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOCOPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOCOPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More